A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two fixed doses (50 mg, 100 mg) of desvenlafaxine sustained-release tablets [Pristiq; Wyeth] in adult outpatients with major depressive disorder

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two fixed doses (50 mg, 100 mg) of desvenlafaxine sustained-release tablets [Pristiq; Wyeth] in adult outpatients with major depressive disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2013

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 19 Jul 2013 Results from a pooled analysis of six studies (NCT00277823, NCT00300378, NCT00384033, NCT00798707, NCT00824291, and NCT00863798) were published in the International Clinical Psychopharmacology.
    • 28 Jun 2009 Results have been presented at the 9th World Congress of Biological Psychiatry.
    • 12 Dec 2007 Results were reported in a media release from Wyeth, and were presented at a major meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top